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ABSTRACT 
Implantation of an indwelling medical device is often required in order to successfully treat a serious medical 
issue.  However, infection of such devices is an ongoing problem, and can occur when microorganisms, 
predominantly Staphylococcus species, adhere to the device surface1.  Biodegradable polymer drug delivery 
technology may be of use in some devices as a means of delivering a high local dose of antimicrobial in order 
to help prevent infection pathogenesis.  In this study the broad spectrum antibiotic rifampicin has been 
formulated with the polymers PLA (Poly(L-Lactide)) and PLGA (Poly(D,L-lactic-co-glycolic acid(65:35)) 
and the in vitro drug release over 1 week analysed.  Based on the release data (Fig. 1A), the PLGA:rifampicin 
formulations of 50:50 and 60:40 were selected for further analysis.  A 4 week drug release study showed that 
over the examined period >95% of the rifampicin load was released from both formulations, however 
increasing the ratio of polymer to drug significantly changed the percentage release profile (Fig. 1B).  
Investigation of antimicrobial activity revealed that both formulations were able to produce consistently large 
zones of inhibition in disk diffusion assays over the 4 weeks examined, indicating successful bacterial 
inhibition (Fig. 1C).  What this preliminary study has revealed is that rifampicin can be readily released from 
PLA and PLGA, and that release can be controlled by adjusting the ratio of polymer to drug.  It has also 
shown that the antimicrobial activity of the rifampicin can be retained for at least 4 weeks.  Therefore 
biodegradable polymers may represent a promising material for use in implanted medical devices as a means 
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Fig.1: A shows the release of rifampicin from a variety of biodegradable polymer formulations into PBS (37°C; 
120rpm) over 1 week. B shows release of rifampicin from PLGA formulations over 4 weeks under the same 
conditions (Statistical analysis by one-way Anova and Tukeys post hoc test, *p  0.05; for all data n=3 ± SEM). C 
shows zones of inhibition produced by the formulations against Staphylococcus aureus after 0 hours/28 days in PBS 
(top = 60:40; bottom = 50:50 PLGA:rifampicin) 
